Phase 3 Open-label, Multicenter, Randomized Study of XY0206 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3-ITD Mutation
Latest Information Update: 29 May 2023
At a glance
- Drugs XY-0206 (Primary) ; Azacitidine; Azacitidine; Cytarabine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Granulocyte colony-stimulating factors; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ALIVE
- Sponsors Shijiazhuang Yiling Pharmaceutical
- 29 May 2023 New trial record